Support the Lochmüller Lab in the annual Cycle for CHEO ride!

On May 5th, Lochmüller Lab team members and friends are participating in the annual CN Cycle for CHEO bike ride to raise funds to ensure that CHEO remains a leader in creating better treatment options and finding new cures so that more kids survive cancer.

We want to raise awareness and funds for cancer research, care and support.

All donations help CHEO continue their life-saving work. Please donate today!

Sponsor Hanns

Sponsor Sally

Sponsor Jarred

Sponsor Emily

Sponsor George

bike-race

Read next...

welcome

Meet The Lab’s New Clinical Members!

Our research team is growing! We are excited to announce three new research staff who have joined the lab this winter, as well as two...
researcher of the year 2025

Dr. Hanns Lochmüller Awarded “Clinical Researcher of the Year” by University of Ottawa Faculty of Medicine

We are thrilled to announce that Dr. Hanns Lochmüller has been awarded the Clinical Researcher of the Year Award by the University of Ottawa Faculty...
Holland study

New Publication: Galactose treatment rescues neuromuscular junction transmission in glutamine-fructose-6-phosphate transaminase 1 (Gfpt1) deficient mice

Congenital Myasthenic Syndromes (CMS) are a group of rare inherited neuromuscular disorders caused by genetic defects at the neuromuscular junction (NMJ). Patients with CMS experience...
award winners

Celebrating Lab Members’ Recent Research Awards

We are thrilled to celebrate Kelly Ho for receiving first place for her poster presentation at this year’s American Society for Pharmacology and Experimental Therapeutics...
New publication - RTD (2)

Meet The Lochmüller Lab’s Newest Members!

Our research team is growing! We are excited to introduce three new members who have recently joined the Lochmüller lab and several students who will...
McMillan smart study (1)

New Clinical Study Examines Safety and Efficacy of IV Onasemnogene Abeparvovec in Broad SMA Cohort

Pediatric neurologist Dr Hugh McMillan publishes clinical study examining the safety and efficacy of IV onasemnogene abeparvovec in the broadest cohort of SMA patients to...